The FDA’s clearance could double Kisqali’s breast cancer market. Elsewhere, Novo is exploring new ways to deliver genetic therapies and Bain is funding a growing CDMO.

The deal is another example of a surge in acquisitions of private biotech assets at a time when public company buyouts have become more sparse. Organon is betting its commercial reach will spur sales ...

Boston, MA – The much-anticipated RE•WORK AI in Healthcare & Pharma Summit is set to take place on November 13-14, 2024, at ...

The FDA previously rejected patritumab deruxtecan over manufacturing issues. Tuesday's study data should boost the companies' case, however.

Summary study results show Ascendis’ drug for achondroplasia could be competitive to BioMarin's Voxzogo, which is the foundation of the latter company's growth plans.

The funding will support mid-stage testing of a drug the company believes to have the potential to treat a range of neurodegenerative conditions.

Warner Biddle and Christi Shaw, two prominent former executives at Gilead’s CAR-T division, will try to turn around an autoimmune cell therapy developer that’s lost most of its value since raising ...

Results presented at ESMO showed tumor response rates that matched the bar set by analysts for success. But they may not yet be enough to dispel doubts around TIGIT as a target.

With a new production line, Sanofi aims to keep it and partner AstraZeneca’s drug Beyfortus in fully supply this RSV season.

The funding, from AMR Action Fund and others, will help U.K.-based F2G complete late testing of a treatment that the FDA rejected one year ago.

Avalere Health is proud to announce the appointment of Corrina Safeio as its new President, Global Marketing and EVP, ...

Final follow-up results suggest Opdivo and Yervoy could be close to a cure for some people with advanced melanoma, shifting how doctors administer follow-up care.